Created from scratch by us.
All of our programs are created by starting with a problem and identifying innovative approaches to addressing it. We are focused on the cutting edge of new science and innovation, and aim to be several years ahead of prevailing trends. View our Innovations
Setipiprant is a selective oral antagonist of the CRTH2 receptor, a receptor where Prostaglandin D2 binds. George Cotsarelis discovered that Prostaglandin D2 seems to play a notable role in hair loss.
Prostaglandin D2 has been found elevated in regions of the male scalp associated with hair loss. Therefore, interfering with this PGD2 receptor could be a potential treatment for hair loss with the promotion of hair growth, or to inhibit the miniaturization process.
Leading Growth Pharma